CA-NOMINUM
21.6.2017 15:02:05 CEST | Business Wire | Press release
Nominum ™, the DNS-based security and services innovation leader, announced today that Bledsoe Telephone Cooperative, which provides phone, broadband internet and IPTV services to subscribers in Tennessee, has deployed the company’s industry-leading Vantio™ CacheServe DNS software to improve speed, security and reliability of its broadband network. Additionally, Bledsoe will use Nominum N2™ ThreatAvert and N2 Secure Consumer to protect both its network and broadband subscribers from malicious cyberattacks like DDoS, phishing, ransomware and other malware.
Bledsoe turned to Nominum to speed up DNS query resolution and ensure thorough safeguards are in place to keep malicious threats from slowing or otherwise negatively impacting performance of its network. With the increasing frequency and severity of cyberthreats impacting service provider networks and their customers, Bledsoe will also deploy Nominum N2 ThreatAvert to thwart DDoS, DNS amplification and Pseudo Random Subdomain (PRSD) attacks.
The telecom operator is also implementing Nominum N2 Secure Consumer to keep subscribers protected from phishing, ransomware and other cyberthreats across all devices and networks, while providing parental control features that enable subscribers to set policies to block inappropriate content and limit time spent online for their children.
“Our previous DNS solution delivered slow response times and lacked the strong security capabilities we now have with Nominum, which resulted in a less than optimal experience for our subscribers,” said Russ Camp, CIO for Bledsoe. “Our goal was to maximize network reliability through the most cost-effective means possible. With Nominum, we have seen a significant difference with consistently better performance and assurance that our network is protected from cyberattacks and hackers. Support call volume has gone down and reliability has gone up—both of which strengthen our brand and generate greater customer loyalty.”
“The combination of Nominum Vantio CacheServe DNS software with the N2 application suite enables service providers to deliver a ‘closed loop’ security experience for their subscribers, from ensuring optimal performance of the network, to protecting the network from DNS-based attacks, to securing subscribers and their devices, to notifications and remediation when a breach has occurred,” said Daniel Blasingame, Vice President of Sales, North America for Nominum. “Operators like Bledsoe recognize the need for ever-greater cyber protections and a scalable network infrastructure given the major growth taking place with adoption of IoT devices and consumers’ increasingly mobile lifestyle. As a partner in their success, our mission is to enable a better, safer and faster internet for their subscribers—and for internet users everywhere.”
Nominum Vantio and N2: Creating a Stronger, Faster and More Secure Internet
The Nominum N2 product suite is designed to optimize and secure consumer and business users’ online activities through robust DNS-based network protection, subscriber/device security and personalized notifications when a breach occurs—delivering a closed loop security experience. Through the combination of Nominum’s industry-leading Vantio CacheServe unified DNS platform and N2, ISPs strengthen their competitive advantage, accelerate revenue growth and increase brand loyalty. The full product suite includes:
- Vantio CacheServe —Offers high network availability and low latency for ISP networks.
- N2 ThreatAvert —Proactively protects ISP networks from cyberthreats with accurate, adaptive and automated technology.
- N2 Secure Consumer —Provides consumers with personalized internet safety solutions such as parental controls, and proactively protects households from malware, ransomware and phishing attacks.
- N2 Secure Business —Security as a Service solution enabling ISPs to easily deploy SMB and enterprise cyberthreat protection to prevent ransomware, phishing, botnets and zero-day malware attacks.
- N2 Reach —In-browser subscriber communications and campaign management platform that is proven to be more effective than email, direct mail, phone calls or text.
About Nominum
Nominum™ is a pioneer and global leader in DNS-based security and services innovation. The Silicon Valley company provides an integrated suite of carrier-grade DNS-based solutions that enable fixed and mobile operators to protect and enhance their networks, strengthen security for business and residential subscribers and offer innovative value-added services that can be monetized. The result is improved service agility, higher ARPU, increased brand loyalty and a strong competitive advantage. More than 130 service providers in over 40 countries trust Nominum to deliver a safe, customizable internet and promote greater value to over half a billion users. Nominum DNS software resolves 1.7 trillion queries around the globe every day—roughly 100 times more transactions than the combined daily volume of tweets, likes, and searches taking place on major web properties. For more information visit nominum.com.
Follow us on Twitter: @nominum https://twitter.com/nominum
Follow us on LinkedIn: https://www.linkedin.com/company/nominum
See us on YouTube: https://www.youtube.com/nominum
Read our latest blogs: http://nominum.com/blog/ | http://nominum.com/tech-blog/
View source version on businesswire.com: http://www.businesswire.com/news/home/20170621005494/en/
Contact:
Nominum
Nancy MacGregor, +1-415-309-5185
PR Director
nancy.macgregor@nominum.com
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
